Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010.
about
Guidance to develop individual dose recommendations for patients on chronic hemodialysis.Strength of evidence for labeled dosing recommendations in renal impairment.Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.
P2860
Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Influence of kidney disease on ...... w chemical entities 1999-2010.
@en
type
label
Influence of kidney disease on ...... w chemical entities 1999-2010.
@en
prefLabel
Influence of kidney disease on ...... w chemical entities 1999-2010.
@en
P2093
P2860
P356
P1476
Influence of kidney disease on ...... w chemical entities 1999-2010.
@en
P2093
Gary R Matzke
John E Murphy
Samantha A Marks
P2860
P304
P356
10.1002/JCPH.604
P577
2015-08-04T00:00:00Z